Advanced search
Publication Cover
The American Journal of Drug and Alcohol Abuse
Encompassing All Addictive Disorders
Volume 38, 2012 - Issue 2
Submit an article Journal homepage
441
Views
12
CrossRef citations to date
0
Altmetric
Research Articles

Treatment Outcome for Flexible Dosing Buprenorphine Maintenance Treatment

Ayman FareedDepartment of Psychiatry, Emory University School of Medicine/Atlanta VA Medical center, Decatur, GA, USACorrespondence[email protected]
, M.D.,
Sreedevi VayalapalliDepartment of Psychiatry, Emory University School of Medicine/Atlanta VA Medical center, Decatur, GA, USA
, M.D.,
Jennifer CasarellaDepartment of Psychiatry, Emory University School of Medicine/Atlanta VA Medical center, Decatur, GA, USA
, M.D. &
Karen DrexlerDepartment of Psychiatry, Emory University School of Medicine/Atlanta VA Medical center, Decatur, GA, USA
, M.D.
Pages 155-160 | Published online: 19 Dec 2011

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Heide Jackson, Kara Mandell, Kimberly Johnson, Debanjana Chatterjee & David J. Vanness. (2015) Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence. Substance Abuse 36:2, pages 226-231.
Read now
Sofie Mauger, Ronald Fraser & Kathryn Gill. (2014) Utilizing buprenorphine–naloxone to treat illicit and prescription-opioid dependence. Neuropsychiatric Disease and Treatment 10, pages 587-598.
Read now
Cheryl Teruya, Robert P. Schwartz$suffix/text()$suffix/text(), Shannon Gwin Mitchell, Albert L. Hasson$suffix/text()$suffix/text(), Christie Thomas, Samantha H. Buoncristiani$suffix/text()$suffix/text(), Yih-Ing Hser, Katharina Wiest, Allan J. Cohen, Naomi Glick, Petra Jacobs, Paul McLaughlin & Walter Ling. (2014) Patient Perspectives on Buprenorphine/Naloxone: A Qualitative Study of Retention During the Starting Treatment with Agonist Replacement Therapies (START) Study. Journal of Psychoactive Drugs 46:5, pages 412-426.
Read now
Brianne Fitzgerald & Betty D. Morgan. (2012) DSM-5 Changes on the Horizon: Substance Use Disorders. Issues in Mental Health Nursing 33:9, pages 605-612.
Read now

Articles from other publishers (8)

Adam J. Gordon, Andrew J. Saxon, Stefan Kertesz, Jessica J. Wyse, Ajay Manhapra, Lewei A. Lin, Wei Chen, Jared Hansen, Derek Pinnell, Tina Huynh, Jacob D. Baylis, Francesca E. Cunningham, Udi E. Ghitza, Gavin Bart, Hong Yu & Brian C. Sauer. (2023) Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug and Alcohol Dependence 248, pages 109902.
Crossref
Lucinda A. Grande, Dave Cundiff, Mark K. Greenwald, MaryAnne Murray, Tricia E. Wright & Stephen A. Martin. (2023) Evidence on Buprenorphine Dose Limits: A Review. Journal of Addiction Medicine Publish Ahead of Print.
Crossref
Michael H. Baca-Atlas & Joseph B. Williams. (2021) Treatment of Opioid Use Disorder Attributed to Fentanyl With High-Dose Buprenorphine. Journal of Clinical Psychopharmacology 41:1, pages 83-85.
Crossref
Marlon Danilewitz & Mark McLean. (2019) High‐dose buprenorphine for treatment of high potency opioid use disorder. Drug and Alcohol Review 39:2, pages 135-137.
Crossref
Viktor Mravčík, Barbara Janíková, Barbora Drbohlavová, Petr Popov & Alessandro Pirona. (2018) The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic. Harm Reduction Journal 15:1.
Crossref
Lisa J. Merlo, Michael D. Campbell, Gregory E. Skipper, Corinne L. Shea & Robert L. DuPont. (2016) Outcomes for Physicians With Opioid Dependence Treated Without Agonist Pharmacotherapy in Physician Health Programs. Journal of Substance Abuse Treatment 64, pages 47-54.
Crossref
Ayman Fareed. (2015) Author's Reply. Journal of Addiction Medicine 9:3, pages 251-252.
Crossref
Mark K. Greenwald, Sandra D. Comer & David A. Fiellin. (2014) Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: Implications for clinical use and policy. Drug and Alcohol Dependence 144, pages 1-11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.